dibenzyldithiocarbamate

Dibenzyldithiocarbamate (BDTC) is a dithiocarbamate derivative that has been investigated as a potential inhibitor of the DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT) for the treatment of glioblastoma. As a structural analog of disulfiram metabolites, it was hypothesized to conjugate with the active-site cysteine of MGMT, thereby sensitizing tumor cells to alkylating agents like temozolomide. However, preclinical research indicates that BDTC is significantly less potent than other dithiocarbamates, such as dimethyldithiocarbamate (MDTC), showing minimal cytotoxicity and poor binding affinity to MGMT. This lack of efficacy is likely due to the steric hindrance caused by its bulky benzyl groups, which prevents effective interaction with the target protein's active site.

Other names

N,N-dibenzyldithiocarbamatedibenzyl dithiocarbamate